Skip to content
Sunday, November 22, 2026
Latest
Regulation United States

Altria units join FDA enforcement guideline lawsuit

A US federal judge let Altria's NJOY and Helix Innovations join a lawsuit over an FDA enforcement guideline on Monday. The judge did not rule on the guideline's legality; a hearing is set for 11 December.

POD - маломощная электронная сигарета
POD - маломощная электронная сигарета. Photographed 2022-06-08. File photo: Pannet / Wikimedia Commons, CC BY-SA 4.0. Image: Pannet Image source · CC BY-SA 4.0 · Display crop and size variants; source image content retained.

Key points

  • A federal judge allowed Altria's NJOY and Helix Innovations to join a lawsuit over an FDA enforcement guideline on Monday.
  • The judge did not decide whether the guideline is lawful, leaving that question open.
  • A hearing in the lawsuit is scheduled for 11 December.
  • Altria chief executive Sal Mancuso said slow FDA review and illegal nicotine products hinder the smoke-free business, according to Fortune.
On this page
  1. Both subsidiaries can defend their products inside the case
  2. Altria’s chief executive ties review delays to competition
  3. Investors marked the shares down slightly
  4. What changes for manufacturers and exporters

Altria’s NJOY and Helix Innovations won permission on Monday to join a lawsuit over an FDA enforcement guideline, though the judge did not decide whether the guideline is lawful.

The case concerns how the FDA pursues certain unauthorised e-cigarettes and nicotine pouches. A hearing is scheduled for 11 December.

Both subsidiaries can defend their products inside the case

Joining the proceeding lets Helix Innovations and NJOY argue for keeping their products on the market while the dispute continues. The source does not say which specific products are at issue or how the guideline defines the products it covers.

The judge’s order settles participation, not substance. No ruling on the merits has been issued, and the December hearing is the next dated step.

Altria’s chief executive ties review delays to competition

Sal Mancuso, Altria’s chief executive, said yesterday that slow FDA review and illegal nicotine products hold back the company’s smoke-free business, according to Fortune. He said both the review process and enforcement against illegal products make competition in nicotine pouches harder.

Mancuso called for leaner review processes that keep high standards, according to Fortune. Fortune also reported that Altria has sued the FDA over its review procedure, so the company is challenging the agency’s process in court separately from the guideline case.

Investors marked the shares down slightly

The shares had already declined yesterday alongside a weaker US market.

The source gives no figure for the size of the guideline’s effect on Altria’s smoke-free sales, and no date for when the FDA issued the guideline.

What changes for manufacturers and exporters

The outcome of the case could shape how the FDA enforces against products without authorisation, which matters to any exporter shipping to the US market. The source does not state the guideline’s scope or whether it covers imports as well as domestic sales, so supply-chain effects remain unconfirmed. VapeBrief’s analysis: the 11 December hearing is the date to watch, and the judge’s refusal to rule on the guideline so far means the enforcement posture stays as it is.

Item Detail Date or status
Joinder of NJOY and Helix Innovations Allowed by a federal judge Monday
Ruling on guideline legality Not decided Pending
Hearing Scheduled in the lawsuit 11 December
Share

Sources

18+ only. This site is for adult readers and provides news and information only. It is not medical, legal or purchase advice. Nicotine is addictive. Always check the official text of any regulation in your market. Health Information

Adrian Cole

Adrian Cole covers vape regulation for VapeBrief. He spent nine years working in e-cigarette export compliance.

About this byline →

Daily Brief newsletter

A concise email at 08:00 U.S. Eastern time each day, with links to the previous day’s published briefs.

Topics of interest

Active immediately, no confirmation click needed. Every email includes an unsubscribe link. See our Privacy Policy.